SCHEMBL2276172

SCHEMBL2276172

CC(C)(C)OC(=O)c1ccc(Oc2ccccc2)cc1NS(=O)(=O)/C=C/c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 1/20 0.46
PPARG P37231 3/20 0.46
ALDH1A1 P00352 4/20 0.45
LMNA P02545 2/20 0.45
HTT P42858 2/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
PTGES2 Q9H7Z7 4/20 0.43
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SCN9A Q15858 1/20 0.40
CYP1A2 P05177 1/20 0.39
RRM1 P23921 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2276179 1.00 CYP2C9 (0.46) CYP2C9CYP2C19PPARGALDH1A1LMNA
SCHEMBL2269092 0.86 CYP2C9 (0.58) CYP2C9CYP2C19PPARGALDH1A1LMNA
SCHEMBL2269088 0.86 CYP2C9 (0.58) CYP2C9CYP2C19PPARGALDH1A1LMNA
SCHEMBL2271253 0.85 PTGES2 (0.47) ALDH1A1LMNAHTTKMT2AMEN1
SCHEMBL2273406 0.85 PTGES2 (0.47) ALDH1A1LMNAHTTKMT2AMEN1
SCHEMBL2274040 0.74 RAB9A (0.46) ALDH1A1LMNAKMT2AMEN1KDM4E
SCHEMBL2274043 0.74 RAB9A (0.46) ALDH1A1LMNAKMT2AMEN1KDM4E
SCHEMBL2273465 0.72 TSHR (0.56) CYP2C9CYP2C19ALDH1A1KDM4EGAA
SCHEMBL14966709 0.72 SRD5A2 (0.48) CYP2C9CYP2C19PPARGALDH1A1LMNA
SCHEMBL2269667 0.71 F10 (0.53) PPARGALDH1A1KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 CYP2C9 841/4885CYP2C19 1098/4885PPARG 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.